Therapeutic Technology

target validated in vivo

Technology Listing:

Novel Prostaglandin Receptor-Mediated Activator as Treatment of Airway CFTR Mutations - 20-04

CBX7 and MEK2: New Targets for Steroid Resistant Asthma - 18-05

Novel Inhibitors of DksA Effective Against Gram-Negative Bacteria - 18-03

Selenocyanate as Antimicrobial Against Lung Infections - 17-09

Targeting CYP11A1 in the Steroidogenic Pathway For Treating Allergic Diseases - 11-17

B Cells Desensitization with an Anti-CD79 Antibody: Therapeutic Approach for Autoimmune Diseases - 11-15

PTPN13: A Novel Target for the Treatment of Pulmonary Fibrosis - 11-09

PIM 1 Kinase Inhibition for the Treatment of Allergic Diseases - 11-06

Novel TLR Inhibitors Prevent Respiratory Syncytial Virus Infection In Vivo - 07-07

MAGP-2: An extracellular factor shown to have pro-angiogenic properties - 06-05

Sulfasalazine as a Treatment for Sarcoidosis - Results of a Clinical Pilot Study - 04-09

Method to prevent biofilm formation in various clinical settings (contact lenses, wounds, cystic fibrosis, etc.) - 04-08

Modulating the transport of thiol-containing molecules for the treatment of lung disease and cancer - 02-16

Liposomal clodronate as a therapy for autoimmune hemolytic anemia - 02-07

TALL-1 and its Receptor BCMA: Molecular Targets for the Development of Therapies Against Autoimmune Diseases - 02-01

Aerosolized Anti-Human CD3 Antibodies Decrease Airway Hyperresponsiveness in Non- Human Primates - 01-01

View list of available Diagnostics.

View list of available Antibodies or Animal models.

View list of available biomedical devices.

For more information, contact Emmanuel Hilaire at HilaireE@njhealth.org.